Type 2 diabetes patients increasingly diagnosed with liver fibrosis: Lancet Study

A groundbreaking Lancet South Asia study has just sounded a major alarm: one in four Type 2 diabetes patients in India is silently developing significant liver fibrosis, a severe scarring that often progresses without noticeable symptoms. This startling finding, uncovered by the DiaFib-Liver Study which screened over 9,000 individuals, positions the liver as the critical 'fourth vulnerable organ' in diabetes care, alongside the eyes, heart, and kidneys, demanding urgent attention from healthcare systems and patients alike. This isn't just about fatty liver; the study strikingly revealed that liver scarring is occurring even in diabetes patients without detectable fat accumulation, challenging long-held assumptions and highlighting the insidious nature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its more severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH). Globally, nearly one-fifth of Type 2 diabetes patients already contend with advanced fibrosis, a figure that surges to almost a quarter in South Asia, underscoring a growing public health crisis exacerbated by rising rates of insulin resistance and obesity. The immediate imperative is for widespread, routine screening using non-invasive tools like the FIB-4 score, as recently advocated by the American Diabetes Association's 2025 guidelines, to catch this silent progression early and enable timely intervention. With promising new therapies like Resmetirom gaining recent FDA approval for MASH with fibrosis, and investigational drugs like efruxifermin showing potential to even reverse cirrhosis, proactive diagnosis and aggressive management are no longer just aspirational—they are becoming essential strategies to avert a tidal wave of advanced liver disease.